The impact of care pathways for exacerbation of Chronic Obstructive Pulmonary Disease: rationale and design of a cluster randomized controlled trial by Vanhaecht, Kris et al.
STUDY PROTOCOL Open Access
The impact of care pathways for exacerbation of
Chronic Obstructive Pulmonary Disease: rationale
and design of a cluster randomized controlled
trial
Kris Vanhaecht
1,2*, Walter Sermeus
1,2, Jan Peers
2, Cathy Lodewijckx
2, Svin Deneckere
2, Fabrizio Leigheb
3,
Marc Decramer
2, Massimiliano Panella
1,3, the EQCP Study Group
Abstract
Background: Hospital treatment of chronic obstructive pulmonary disease (COPD) frequently does not follow
published evidences. This lack of adherence can contribute to the high morbidity, mortality and readmissions rates.
The European Quality of Care Pathway (EQCP) study on acute exacerbations of COPD (NTC00962468) is undertaken
to determine how care pathways (CP) as complex intervention for hospital treatment of COPD affects care
variability, adherence to evidence based key interventions and clinical outcomes.
Methods: An international cluster Randomized Controlled Trial (cRCT) will be performed in Belgium, Italy, Ireland
and Portugal. Based on the power analysis, a sample of 40 hospital teams and 398 patients will be included in the
study. In the control arm of the study, usual care will be provided. The experimental teams will implement a CP as
complex intervention which will include three active components: a formative evaluation of the quality and
organization of care, a set of evidence based key interventions, and support on the development and
implementation of the CP. The main outcome will be six-month readmission rate. As a secondary endpoint a set of
clinical outcome and performance indicators (including care process evaluation and team functioning indicators)
will be measured in both groups.
Discussion: The EQCP study is the first international cRCT on care pathways. The design of the EQCP project is
both a research study and a quality improvement project and will include a realistic evaluation framework
including process analysis to further understand why and when CP can really work.
Trial Registration number: NCT00962468
Background
Healthcare is changing towards more patient focused
care. The organization of the care process related to
quality, efficiency and accessibility is one of the main
areas of interest within the next years for clinicians,
healthcare managers and policy makers. A main method
to (re)organize a care process is the development and
implementation of a care pathway. Care pathways, also
known as clinical pathways or critical pathways, are
used worldwide for a variety of patient groups [1-7]. A
care pathway is defined as a complex intervention for
the mutual decision making and organization of predict-
able care for a well-defined group of patients during a
well defined period. Defining characteristics of pathways
includes: an explicit statement of the goals and key ele-
ments of care based on evidence, best practice and
patient expectations; the facilitations of the communica-
tion and coordination of roles, and sequencing the activ-
ities of the multidisciplinary care team, patients and
their relatives; the documentation, monitoring, and eva-
luation of variances and outcomes; and the identification
of relevant resources [4,8,9].
* Correspondence: kris.vanhaecht@med.kuleuven.be
1European Pathway Association, Kapucijnenvoer 35/4, B-3000 Leuven,
Belgium
Full list of author information is available at the end of the article
Vanhaecht et al. Trials 2010, 11:111
http://www.trialsjournal.com/content/11/1/111
TRIALS
© 2010 Vanhaecht et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.A care pathway is explicitly defined as a “complex
intervention” [4,8-11]. Complex interventions in health-
care, whether therapeutic or preventive, comprise a
number of interacting components which seem essential
to the proper functioning of the intervention although
the “active component’’ of the intervention that is effec-
tive, is difficult to specify. Considering a spectrum of
low to high complexity such as developing a drug would
be at the low end of complexity spectrum and the eva-
luation of the effect of a stroke unit would be at the
high end of the spectrum. The greater the difficulty in
defining precisely what the “active component” of an
intervention is, and how they relate to each other, the
greater the likelihood that you are dealing with a com-
plex intervention [12-14]. Pathways in the line of stroke
units seem to be at the higher end of the complexity
spectrum. Active ingredients of a care pathway complex
intervention might be the level of multidisciplinary
teamwork, the integration of a package of evidence
based key interventions and the active follow-up of the
care process [6].
A recent Cochrane review concludes that clinical path-
ways are associated with reduced in-hospital complica-
tions and improved documentation without negatively
impacting on length of stay and hospital costs [15]. The
effects are however still quite small in comparison of
what we might expect theoretically. One possible reason
is the high variability in effect from one organisation to
another organisation what seems to stress that context
factors might be extremely important [9,16,17]. These
context factors are not taking well in these meta-analyses
as context is really stripped off. An indicator of context
influence is the heterogeneity of the meta-analysis, which
seems to be quite high in the Rotter meta-analysis paper
[15]. Large multicenter trials including information on
the mechanisms used and the context of the involved
organizations will be important to fully understand why
and when pathways lead to their effect [9,18].
To evaluate pathway effectiveness the European Pathway
Association, an international not for profit association,
launched the European Quality of Care Pathways (EQCP)-
study on exacerbation of Chronic Obstructive Pulmonary
Disease (COPD) [18]. COPD is worldwide a leading cause
of acute hospital admission [19]. Patients with COPD
exacerbation need multidisciplinary care and the coordina-
tion of the care process among multiple caregivers is com-
plex [20]. Thirty five percent of COPD patients are
admitted because of acute exacerbation within one year
[21]. Up to 40% of admitted patients having two or more
readmissions a year [22,23]. A systematic review about in-
hospital management of COPD exacerbation showed that
implementation of care processes recommended by world-
wide accepted guidelines is very poor and show high var-
iance, especially for performance of non pharmacological
interventions [24]. Also Decramer et al. (2003) found sev-
eral important deviations from international guidelines in
the management of COPD by pulmonologists and general
practitioners [25].
Up to now two non-randomized trials about the
impact of a care pathway for inpatient management of
COPD exacerbation are published [26,27]. The studies
have been conducted between 2000 and 2001, and the
methodology was rather weak. However the studies sug-
gest that a COPD exacerbation care pathway improves
performance with regard to diagnostic assessment and
use of standing orders, and that it may reduce length of
stay and the number of hospitalisations.
Objectives
The primary goal of the EQCP study on COPD is to
evaluate the care pathway effectiveness in acute hospi-
tals. A secondary goal is to understand how and under
which circumstances the implementation of a pathway
for COPD is successful.
Methods
The project
The European Quality of Care Pathways (EQCP) study
is an international multicentre research project launched
the European Pathway Association (E-P-A) http://www.
E-P-A.org, an international not for profit association
[18]. The E-P-A is collaborating with the Center for
Health Services and Nursing Research of the Faculty of
Medicine of the Catholic University Leuven (Belgium)
and the School of Public Health of the Amedeo Avoga-
dro University of Eastern Piedmont (Italy) for the scien-
tific lead of the this study. The study runs in four
countries: Belgium, Ireland, Italy and Portugal. In each
country, a research centre is coordinating the project in
the own country based on the international agreed pro-
tocol. In Belgium the lead coordinating centre is the
Center for Health Services and Nursing Research of the
Faculty of Medicine of the Catholic University Leuven.
For Ireland, the lead centre is the Health Service Execu-
tive in Dublin. In Italy, the School of Public Health of
the Amedeo Avogadro University of Eastern Piedmont
is coordinating the project with support from ARESS
Piemonte. In Portugal, the lead coordinating centre is
National School of Public Health in Lisbon. In each of
the four countries hospitals will be selected by E-P-A in
close cooperation with a national coordinator. In every
participating hospital a pathway facilitator is appointed
as local facilitator for implementing the care pathway.
The pathway facilitator is trained by the E-P-A team in
implementing care pathways, except for Belgium where
hospitals were selected among members of the Belgian-
Dutch Clinical Pathway Network and all pathway facili-
tators were trained before in the network [18].
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To evaluate the effect of a care pathway, a cluster Ran-
domized Controlled Trial (cRCT) will be used [12-14].
In cRCTs organizations, rather than individuals, are ran-
d o m i z e dt oa ni n t e r v e n t i o na n dac o n t r o lg r o u p ,a n d
outcomes are measured on individual level within the
clusters [14]. Each cluster consist of patients hospita-
lized for a COPD exacerbation in a particular hospital
and cared for by a specific multidisciplinary team.
Stratified randomization will be used to assign hospi-
tals to an intervention group (development and imple-
mentation of an evidence based care pathway) and a
control group (no intervention/usual care). Literature
showed that several organizational factors could have
significant impact on performance of key interventions
and outcomes. To ensure that hospitals in both arms
are in balance, hospitals will be stratified on country-
level, according to the following variables: hospital type
(teaching versus non teaching), hospitals size (< 600 and
≥600 beds) and annual volume of COPD-patients (< 300
and ≥300). Furthermore, the following organizational
factors will be explored: availability of an early discharge
scheme, presence of local guidelines about follow-up of
patients after discharge, presence of a formal pulmonary
rehabilitation program, availability of non-invasive venti-
lation, and annual volume of patients treated for COPD
exacerbation. These variables will be treated as covari-
ates in the data analysis. To the hospitals included in
t h ec o n t r o lg r o u pw i l lb eo f f e r e dt h eo p p o r t u n i t yt o
develop a care pathway one year later, based on the pro-
tocol and experience gained in the experimental group,
in order to increase their participation. By this means
the design incorporated some characteristics of a step
wedge design in which the implementation of the inter-
vention is spread over time (see figure 1).
Inclusion - exclusion criteria
Organizations will be included if they will provide writ-
ten agreement to participate and agree that they will not
develop and implement a pathway for COPD within the
time frame of the study when randomized in the control
group. All consecutive patients admitted for COPD
exacerbation will be included in the study if (i) they will
provide written informed consent; (ii) they will be hospi-
talized for at least 48 hours, (iii) they will be admitted
on the ward where the COPD exacerbation is usually
treated (respiratory ward, geriatric ward, general medi-
cine ward) and (iv) if they will be able to understand
and read the native language. Each patient will be
included only once in the study at initial admission,
even if the patient will be hospitalized more than once
during the study period. Patients will be excluded from
the study if they will require invasive positive pressure
ventilation, or if they are already included in another
study of which the measurements could influence the
measurements or outcomes of the EQCP-study.
Study sample
Sample size calculation in a cRCT is based on the
improvement in the main outcome parameters [13,14].
The selection of main outcomes for the EQCP-study is
based on three criteria: frequency of use in the literature,
opinions of experts and timing of the research project
with respect to organizational constraints (sustainability
of the design, time to include patients). Based on these
criteria, six-month readmission rate was identified as the
main study outcome for in-hospital management of
COPD exacerbation ([24]; Lodewijckx C, Sermeus W,
Vanhaecht K, Panella M, Deneckere S, Leigheb F, Troos-
ters T, Decramer M. Selection of indicators for research
on COPD care pathways: an international Delphi study.
submitted). Two other important outcome parameters
are 1-year mortality and length of in-hospital stay. Based
on a power of 80% and an a of 0.05 (two-sided), 296
patients per arm are needed to observe a 10 percent
reduction rate in readmission of 41% to 30% [28,29].
After adjustment for the cluster design, based on two
previous cRCT by Panella et al [30,31] (ICC: 0.018; IFF:
1.342; n = 20) the effective sample size increased to 398
patients per arm. This means that, based on a number of
20 consecutive admitted patients in each unit, 20 hospi-
tals should be included both in each intervention and
control groups. As four countries are actually involved in
the study, every country has to enroll at least ten hospi-
tals that have to be randomized into five cases and five
controls [30,31].
The complex intervention: care pathway implementation
in the experimental arm
The care pathway will include three active components:
(i) A formative evaluation on the quality and organiza-
tion of the care process that will be performed by
measuring performance of key interventions (see figure
2). These interventions are the most important interven-
tions which have impact on the quality of care or the
length of stay. They are performed by the medical
Figure 1 The EQCP study design.
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interventions are given in the domain of medication, the
laboratory tests, patient information and discharge
planning.
Furthermore a set of team indicators will be measured.
Feedback will be provided on the data obtained to help
the teams in understanding their bottlenecks and the
actual overall organization of the care process. Therefore
a pretest will be performed at 6 month before develop-
ing the care pathway during a 2-3 months period. Dur-
ing this pretest, usual care for 20 consecutive patients is
measured against a set of key-interventions (see ii). All
data will be transferred to the research center for analy-
sis. A formative feedback report will be produced
describing the relative performance of the team against
the protocol and against the performance of all other
teams in the study. (ii) A set of evidence based key
interventions will be provided to the multidisciplinary
team. This set is based on an extensive literature review,
Map of Medicine® http://www.mapofmedicine.com and
on consensus by international clinical experts using a
Delphi-survey ([18,24] Lodewijckx C, Sermeus W,
Vanhaecht K, Panella M, Deneckere S, Leigheb F,
Troosters T, Decramer M. Selection of indicators for
research on COPD care pathways: an international Del-
phi study. submitted). The key interventions and out-
comes include both in-hospital interventions and
information for a safe discharge. (iii) The pathway facili-
tators will be supported to improve the organization of
the care process by developing and implementing a care
pathway, based on the findings of the evaluation of the
care process and the set of evidence based key interven-
tions. The pathway facilitators make use of a care path-
way implementation protocol based on the Deming-
PDSA cycle which is generally accepted as the standard
method for quality improvement. Meetings with the
pathway facilitators are organized to present and discuss
the feedback report and to discuss actual bottlenecks in
implementing the care pathway. Change will be sup-
ported by giving the possibility to exchange best prac-
tices among participants. During these meetings local
clinical champions and team change experts will help
and stimulate the pathway facilitators to effective knowl-
edge sharing processes [18].
The control group
In the control group the complex intervention will not
be implemented and these teams will provide usual care.
The control hospitals agree not to change their actual
organization of the care process and do not develop a
care pathway during the study period. The team mem-
b e r sw i l lp r o v i d ec a r ei nt h es a m ew a ya st h e yw e r e
doing before the start of the study.
Measurements
To measure the effect of the care pathways on the pro-
cess and outcome indicators, a set of process and
outcome indicators to evaluate the effectiveness of in-
hospital management of COPD exacerbation was
developed based on literature [24]. Following literature
sources were reviewed: (I) the guidelines of Global
Initiative for Chronic Obstructive Pulmonary Disease
[20]; (II) the guidelines of the American Thoracic
Society-European Respiratory Society Task Force [32];
(III) an extensive review on management of COPD
exacerbation published in 2006 by Rodriguez-Roisin
[33]; (IV) the European Respiratory Monograph, a
book on the management of COPD, published by the
European Respiratory Society (ERS) in 2006 [34], (V)
The guidelines of the National Institute for Clinical
Excellence (NICE) (2004) [35], (VI) two process flows
regarding management of COPD exacerbation in Map
of Medicine [36] and (VII) a systematic review about
in-hospital management of COPD exacerbation [24].
Additionally, three controlled trials about impact of
COPD pathways or reviews of COPD and pathways
[26,27,37], and 11 COPD outcome studies were
reviewed [28,29,39-46]. Consent about the final set of
indicators was obtained using an international Delphi
study ([18]; Lodewijckx C, Sermeus W, Vanhaecht K,
Panella M, Deneckere S, Leigheb F, Troosters T,
Decramer M. Selection of indicators for research on
COPD care pathways: an international Delphi study.
submitted). These indicators were translated in con-
crete measurements by a multidisciplinary expert panel
during a consensus meeting: a medical doctor, a phy-
siotherapist, a clinical nurse specialist and the
researchers of the EQCP-study [18].
To further understand why pathways work, informa-
tion on the context of the organization is important.
Within the EQCP study a set of both generic and
COPD specific context indicators and team structure
indicators will be developed based on literature
review, an international Delphi study and expert opi-
nion [18].
Figure 2 The EQCP complex intervention.
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The study is registered as a cluster randomized clinical
trial at clinicaltrials.gov (identifier: NCT00962468). The
ethical approval will be country specific, but overall ethi-
cal approval will be sustained on three levels: (i) Ethical
approval by the ethical committee of the coordinating
centre on country level (ii) Ethical approval with regard
to the participation in the intervention will be sought on
cluster level, namely by the ethical committee of each of
the participating hospitals. These committees can agree
or disagree with the overall approval of the coordinating
centre. As indicated by the Medical Research Council,
patient’s consent to participate in the study is not possi-
ble, because randomization occurred at the hospital
level and not on patient level. Moreover the aim of the
study is to improve adherence to evidence based care
through clinical pathways in the intervention group. In
the control group, no intervention will be implemented
and patients thus will receive usual care. Therefore
experimental as well as control group should not imply
any risk for the patients included. (iii) Individual
informed consent will be sought from the patient with
regard to the access of the patient record and participa-
tion in surveys. At the present time the approval of the
ethical committee of the coordinating centre at Leuven
University was obtained (identifier: ML5617) and the
proposal is submitted for approval in Portugal, Italy and
Ireland.
Discussion
The EQCP study is the first international cluster rando-
mized controlled trial on the effect of care pathways [18].
Within this study a cRCT design is combined with a rea-
listic evaluation approach [47]. In this way the differences
between the experimental and control arms can be ana-
lyzed but also the process evaluations within the experi-
mental arm itself can be followed-up and evaluated [48].
As suggested by Berwick in 2008 it is not only important
to understand if an intervention works but why and
under what circumstances it works [16]. The approach in
the EQCP study will allow us to analyze if pathways work
but also provide informationo nt h ew h e na n dh o w[ 1 8 ] .
Within this international trial, three active ingredients
define the complex intervention: the feedback on the
actual situation, the information on the evidence based
key interventions and the implementation and design
process.
Hawe and colleagues argue that the crucial point in
the evaluation of complex interventions lies in what is
standardized and that in complex interventions, the
function and process of the intervention should be stan-
dardized and not only the components themselves [49].
This argument is important for pathway research and
was previously described by Panella et al [10]. Rather
than defining the components of the intervention as
standard, what should be defined as standard are the
steps in the change process that the elements are pur-
porting to facilitate or the key functions that they are
meant to have [49]. In pathway research the pathway
process or quality improvement cycle that is run
through is part of the intervention. In that way the
improvement and implementation process is included as
o n eo ft h eb a s i ca c t i v ei n g r e d i e n t s .O n ec h a l l e n g ei n
multicenter trials on pathways, or quality improvement
methods in general, or in comparing pathways from or
between different organizations is to understand the
context. Pawson & Tilley define that an action is causal
only if its outcome is triggered by a mechanism acting
in a context (context + mechanism = outcome) [47].
They argue that programs work (so have good out-
comes) only insofar as they introduce the appropriate
ideas and opportunities (the mechanism) to groups in
the appropriate social and cultural conditions (the con-
text) [16,47]. This realistic evaluation paradigm has
already been used in pathway research [4] and was
recently suggested by Berwick on the science of
improvement [16]. For pathways the mechanism will
need to be based on the basic active ingredients as
described above but the fine-tuning of the intervention
will be based on the actual bottlenecks and on the con-
text of the organization and multidisciplinary team
involved. Therefore in the actual international cRCT on
pathway also a set of team indicators and organizational
factors are measured. The process and outcome indica-
tors will provide data to understand if pathways work,
but the team indicators will be of help in understanding
why and how they work.
With this study E-P-A will be able to influence health
professionals and hospital managers in actively improv-
ing the quality and efficiency of care [18]. The teams
receive support in the re-organization of the COPD care
processes and can later use this implementation knowl-
edge in other care processes. Teams will receive feed-
back on their actual organization including benchmark
data with other international teams. In this way the
design of the EQCP project is both a research study and
a quality improvement project.
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